Cannabis Law Report

AUGUST 18, 2022

17, 2022 – PRESS RELEASE – Raising the standard for cannabis and hemp testing, ACS Laboratory , the largest hemp and cannabis testing facility in the eastern U.S., Using the data collected, ACS Laboratory extracted the strictest requirements per category to create the National Hemp Testing Panel and corresponding Certificate of Analysis.

Compliance 52

Compliance Compliance Hemp Research and Development 52

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA).

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

APRIL 14, 2022

Cannabis businesses that are ill-prepared for these regulatory requirements risk facing litigation, enforcement actions, fines or penalties, and negative publicity, while those taking a proactive approach to compliance may find opportunities to mitigate and even monetize those risks. Next Steps.

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. . BUFFALO, N.Y. , Aug.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

JUNE 1, 2021

Remains on track to achieve positive Adjusted EBITDA during the second half of FY 2022. opportunities in Fiscal 2022.” In Q1 2022, Canopy has expanded its portfolio of THC beverages with Tweed Iced Tea beverages (available in lemon and raspberry flavors, both with 5 mg THC) now shipping. Net revenue. Adjusted EBITDA 3.

Data 95

Data Vaping Supply Chain Business 95

Cannabis Law Report

AUGUST 6, 2021

Adjusted EBITDA loss in Q1 2022 was $64 million , a $29 million narrower loss versus Q1 2021 driven by higher sales and lower operating expenses. Adjusted EBITDA loss in Q1 2022 was negatively impacted by a $10.1 First Quarter Fiscal 2022 Financial Summary. (in Highlights. in millions of Canadian. dollars, unaudited).

Vaping 105

Vaping Research and Development Data Business 105